We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Like a weed growing through an asphalt crack, nature and markets always seem to find a way to recover. After a brutal bear market, an economic slowdown, or a recession takes place, an influx of mergers and acquisitions is one sign that business is picking up again. Why is this? When a larger company acquires a smaller company, the larger company must have the following:
1. The cash or stock on hand to complete the deal.
2. A risk-on, growth mindset, rather than a defensive mindset.
3. An idea that economy has turned or will be healthy enough to sustain the thought process behind the deal.
“Merger Monday” is a term used on Wall Street to label the tendency for companies to announce large deals at the start of the week. Today, details of two potential mega-deals were announced.
Horizon Therapeutics
Amgen Inc (AMGN), a $147 billion-dollar therapeutic company, is embarking on its largest acquisition, Ireland-based Horizon Therapeutics . While the acquisition news is not a huge surprise, there were some twists and turns in the road before the deal was agreed upon. Unless the agreement changes last minute, Amgen will buy Horizon for a whopping $26 billion or $116.50 a share (shares closed at $97 Friday).
Late last month, Zacks reported that Horizon held preliminary discussions with industry giants Sanofi (SNY), Johnson and Johnson (JNJ - Free Report) , and Amgen. The interest from three of the biotech industry’s juggernauts sent shares of Horizon jumping 27% last month. Eventually, Sanofi and Johnson and Johnson backed out of the deal due to valuation concerns, leaving the door open for Amgen.
Both Horizon and Amgen have had positive momentum in recent years. In early 2020, the FDA approved Horizon’s biggest drug, Tepezza, a treatment for thyroid eye disease. Meanwhile, Amgen’s deep pipeline of drugs has propelled the company to earn billions in profits and outperform most of its peers. Amgen and Horizon are members of the Medical – Biomedical and Genetics Group, a top 22% Zacks ranked group.
Image Source: Zacks Investment Research
Pictured: AMGN (green) & HZNP (blue) have outperformed the S&P 500 over the past year.
Coupa Software
Private equity giant Thoma Bravo sees the recent tech crisis as an opportunity. Earlier today, Coupa Software announced that Thoma Bravo would purchase the company for 6.15 billion in cash or a 30% premium to last week’s close. Coupa, a cloud-based enterprise software company, saw its shares slide this year as macroeconomic concerns and slowing growth took their toll on the software industry.
Image Source: Zacks Investment Research
Pictured: While COUP's stock has fallen over the past year, Zacks Revenue Estimates suggest the company is turning the corner.
Despite the rough year in 2021, Zacks Revenue estimates show the company turning the corner in 2023 (revenue for the forward 12 months pictured above). Early in today’s session, investors welcomed the deal. Box Inc (BOX - Free Report) vaulted higher by more than 7% after a JP Morgan (JPM - Free Report) upgrade. MongoDB (MDB),Splunk , and the IShares Software ETF (IGV - Free Report) were solidly green despite the mildly red Nasdaq.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Shutterstock
The Return of "Merger Monday"
Like a weed growing through an asphalt crack, nature and markets always seem to find a way to recover. After a brutal bear market, an economic slowdown, or a recession takes place, an influx of mergers and acquisitions is one sign that business is picking up again. Why is this? When a larger company acquires a smaller company, the larger company must have the following:
1. The cash or stock on hand to complete the deal.
2. A risk-on, growth mindset, rather than a defensive mindset.
3. An idea that economy has turned or will be healthy enough to sustain the thought process behind the deal.
“Merger Monday” is a term used on Wall Street to label the tendency for companies to announce large deals at the start of the week. Today, details of two potential mega-deals were announced.
Horizon Therapeutics
Amgen Inc (AMGN), a $147 billion-dollar therapeutic company, is embarking on its largest acquisition, Ireland-based Horizon Therapeutics . While the acquisition news is not a huge surprise, there were some twists and turns in the road before the deal was agreed upon. Unless the agreement changes last minute, Amgen will buy Horizon for a whopping $26 billion or $116.50 a share (shares closed at $97 Friday).
Late last month, Zacks reported that Horizon held preliminary discussions with industry giants Sanofi (SNY), Johnson and Johnson (JNJ - Free Report) , and Amgen. The interest from three of the biotech industry’s juggernauts sent shares of Horizon jumping 27% last month. Eventually, Sanofi and Johnson and Johnson backed out of the deal due to valuation concerns, leaving the door open for Amgen.
Both Horizon and Amgen have had positive momentum in recent years. In early 2020, the FDA approved Horizon’s biggest drug, Tepezza, a treatment for thyroid eye disease. Meanwhile, Amgen’s deep pipeline of drugs has propelled the company to earn billions in profits and outperform most of its peers. Amgen and Horizon are members of the Medical – Biomedical and Genetics Group, a top 22% Zacks ranked group.
Image Source: Zacks Investment Research
Pictured: AMGN (green) & HZNP (blue) have outperformed the S&P 500 over the past year.
Coupa Software
Private equity giant Thoma Bravo sees the recent tech crisis as an opportunity. Earlier today, Coupa Software announced that Thoma Bravo would purchase the company for 6.15 billion in cash or a 30% premium to last week’s close. Coupa, a cloud-based enterprise software company, saw its shares slide this year as macroeconomic concerns and slowing growth took their toll on the software industry.
Image Source: Zacks Investment Research
Pictured: While COUP's stock has fallen over the past year, Zacks Revenue Estimates suggest the company is turning the corner.
Despite the rough year in 2021, Zacks Revenue estimates show the company turning the corner in 2023 (revenue for the forward 12 months pictured above). Early in today’s session, investors welcomed the deal. Box Inc (BOX - Free Report) vaulted higher by more than 7% after a JP Morgan (JPM - Free Report) upgrade. MongoDB (MDB), Splunk , and the IShares Software ETF (IGV - Free Report) were solidly green despite the mildly red Nasdaq.